IDYA Strangle Strategy
IDYA (IDEAYA Biosciences, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IDYA (IDEAYA Biosciences, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.54B, a beta of -0.05 versus the broader market, a 52-week range of 16.9-39.28, average daily share volume of 1.2M, a public-listing history dating back to 2019, approximately 131 full-time employees. These structural characteristics shape how IDYA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.05 indicates IDYA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on IDYA?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current IDYA snapshot
As of May 15, 2026, spot at $28.16, ATM IV 65.50%, IV rank 8.89%, expected move 18.78%. The strangle on IDYA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on IDYA specifically: IDYA IV at 65.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a IDYA strangle, with a market-implied 1-standard-deviation move of approximately 18.78% (roughly $5.29 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IDYA expiries trade a higher absolute premium for lower per-day decay. Position sizing on IDYA should anchor to the underlying notional of $28.16 per share and to the trader's directional view on IDYA stock.
IDYA strangle setup
The IDYA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IDYA near $28.16, the first option leg uses a $29.57 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IDYA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IDYA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $29.57 | N/A |
| Buy 1 | Put | $26.75 | N/A |
IDYA strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
IDYA strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on IDYA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on IDYA
Strangles on IDYA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IDYA chain.
IDYA thesis for this strangle
The market-implied 1-standard-deviation range for IDYA extends from approximately $22.87 on the downside to $33.45 on the upside. A IDYA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current IDYA IV rank near 8.89% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IDYA at 65.50%. As a Healthcare name, IDYA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IDYA-specific events.
IDYA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IDYA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IDYA alongside the broader basket even when IDYA-specific fundamentals are unchanged. Always rebuild the position from current IDYA chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on IDYA?
- A strangle on IDYA is the strangle strategy applied to IDYA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With IDYA stock trading near $28.16, the strikes shown on this page are snapped to the nearest listed IDYA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are IDYA strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IDYA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 65.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IDYA strangle?
- The breakeven for the IDYA strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IDYA market-implied 1-standard-deviation expected move is approximately 18.78%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on IDYA?
- Strangles on IDYA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IDYA chain.
- How does current IDYA implied volatility affect this strangle?
- IDYA ATM IV is at 65.50% with IV rank near 8.89%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.